CN111991524A - Traditional Chinese medicine composition for convalescent period of neocoronary pneumonia infection and preparation method thereof - Google Patents
Traditional Chinese medicine composition for convalescent period of neocoronary pneumonia infection and preparation method thereof Download PDFInfo
- Publication number
- CN111991524A CN111991524A CN202010890639.7A CN202010890639A CN111991524A CN 111991524 A CN111991524 A CN 111991524A CN 202010890639 A CN202010890639 A CN 202010890639A CN 111991524 A CN111991524 A CN 111991524A
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- chinese medicine
- medicine composition
- pneumonia infection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010035664 Pneumonia Diseases 0.000 title claims abstract description 47
- 239000003814 drug Substances 0.000 title claims abstract description 46
- 239000000203 mixture Substances 0.000 title claims abstract description 42
- 208000015181 infectious disease Diseases 0.000 title claims abstract description 41
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 244000269722 Thea sinensis Species 0.000 claims abstract description 16
- 235000006468 Thea sinensis Nutrition 0.000 claims abstract description 16
- 235000020279 black tea Nutrition 0.000 claims abstract description 16
- 241000208340 Araliaceae Species 0.000 claims description 18
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 18
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 18
- 235000008434 ginseng Nutrition 0.000 claims description 18
- 239000000284 extract Substances 0.000 claims description 16
- 238000000605 extraction Methods 0.000 claims description 16
- 239000002994 raw material Substances 0.000 claims description 14
- 244000268590 Euryale ferox Species 0.000 claims description 13
- 235000006487 Euryale ferox Nutrition 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 238000010992 reflux Methods 0.000 claims description 9
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 8
- 244000249214 Chlorella pyrenoidosa Species 0.000 claims description 8
- 235000007091 Chlorella pyrenoidosa Nutrition 0.000 claims description 8
- 235000002722 Dioscorea batatas Nutrition 0.000 claims description 8
- 235000006536 Dioscorea esculenta Nutrition 0.000 claims description 8
- 240000001811 Dioscorea oppositifolia Species 0.000 claims description 8
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 claims description 8
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 8
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 6
- 235000013399 edible fruits Nutrition 0.000 claims 6
- 244000077995 Coix lacryma jobi Species 0.000 claims 5
- 244000119298 Emblica officinalis Species 0.000 claims 4
- 235000015489 Emblica officinalis Nutrition 0.000 claims 4
- 238000001914 filtration Methods 0.000 claims 2
- 238000002156 mixing Methods 0.000 claims 2
- 210000000582 semen Anatomy 0.000 claims 2
- 239000009609 fructus phyllanthi Substances 0.000 claims 1
- 229940107131 ginseng root Drugs 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 238000002791 soaking Methods 0.000 claims 1
- 238000005303 weighing Methods 0.000 claims 1
- 238000011084 recovery Methods 0.000 abstract description 34
- 241000675108 Citrus tangerina Species 0.000 abstract description 12
- 230000009471 action Effects 0.000 abstract description 4
- 201000010099 disease Diseases 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 238000009472 formulation Methods 0.000 abstract description 3
- 230000007246 mechanism Effects 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000843 powder Substances 0.000 description 14
- 210000004072 lung Anatomy 0.000 description 10
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 8
- 210000000952 spleen Anatomy 0.000 description 8
- 208000000059 Dyspnea Diseases 0.000 description 7
- 206010013975 Dyspnoeas Diseases 0.000 description 7
- 241000756042 Polygonatum Species 0.000 description 7
- 230000007812 deficiency Effects 0.000 description 7
- 208000013220 shortness of breath Diseases 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 208000025721 COVID-19 Diseases 0.000 description 4
- 208000035473 Communicable disease Diseases 0.000 description 4
- 235000002723 Dioscorea alata Nutrition 0.000 description 4
- 235000005362 Dioscorea floribunda Nutrition 0.000 description 4
- 235000004868 Dioscorea macrostachya Nutrition 0.000 description 4
- 235000005361 Dioscorea nummularia Nutrition 0.000 description 4
- 235000005360 Dioscorea spiculiflora Nutrition 0.000 description 4
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- 235000004879 dioscorea Nutrition 0.000 description 4
- 235000004515 gallic acid Nutrition 0.000 description 4
- 229940074391 gallic acid Drugs 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 4
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 3
- 206010000060 Abdominal distension Diseases 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 229920002774 Maltodextrin Polymers 0.000 description 3
- 239000005913 Maltodextrin Substances 0.000 description 3
- -1 Mannose oligosaccharides Chemical class 0.000 description 3
- 208000022531 anorexia Diseases 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 206010061428 decreased appetite Diseases 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 description 3
- 229940030275 epigallocatechin gallate Drugs 0.000 description 3
- 206010016256 fatigue Diseases 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- LVJJFMLUMNSUFN-UHFFFAOYSA-N gallocatechin gallate Natural products C1=C(O)C=C2OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C1OC(=O)C1=CC(O)=C(O)C(O)=C1 LVJJFMLUMNSUFN-UHFFFAOYSA-N 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 229940035034 maltodextrin Drugs 0.000 description 3
- 229920001542 oligosaccharide Polymers 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- LSHVYAFMTMFKBA-PZJWPPBQSA-N (+)-catechin-3-O-gallate Chemical compound O([C@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-PZJWPPBQSA-N 0.000 description 2
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 2
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 2
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 2
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 2
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- FBFMBWCLBGQEBU-GYMUUCMZSA-N 20-gluco-ginsenoside-Rf Natural products O([C@](CC/C=C(\C)/C)(C)[C@@H]1[C@H]2[C@H](O)C[C@H]3[C@](C)([C@]2(C)CC1)C[C@H](O[C@@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1C(C)(C)[C@@H](O)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 FBFMBWCLBGQEBU-GYMUUCMZSA-N 0.000 description 2
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 2
- 241001061264 Astragalus Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 2
- 241001678559 COVID-19 virus Species 0.000 description 2
- 208000034657 Convalescence Diseases 0.000 description 2
- 241000711573 Coronaviridae Species 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 235000007056 Dioscorea composita Nutrition 0.000 description 2
- 235000009723 Dioscorea convolvulacea Nutrition 0.000 description 2
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 2
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 2
- 229920002079 Ellagic acid Polymers 0.000 description 2
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 2
- HVXHJNVYRXRHNX-UHFFFAOYSA-N Garcinone B Chemical compound O1C(C)(C)C=CC2=C(C(=O)C=3C(=CC(O)=C(C=3O)CC=C(C)C)O3)C3=CC(O)=C21 HVXHJNVYRXRHNX-UHFFFAOYSA-N 0.000 description 2
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 2
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 2
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 2
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 235000006350 Ipomoea batatas var. batatas Nutrition 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 description 2
- 101100033674 Mus musculus Ren2 gene Proteins 0.000 description 2
- IKMDFBPHZNJCSN-UHFFFAOYSA-N Myricetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC(O)=C(O)C(O)=C1 IKMDFBPHZNJCSN-UHFFFAOYSA-N 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 2
- DWCSNWXARWMZTG-UHFFFAOYSA-N Trigonegenin A Natural products CC1C(C2(CCC3C4(C)CCC(O)C=C4CCC3C2C2)C)C2OC11CCC(C)CO1 DWCSNWXARWMZTG-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 229960005305 adenosine Drugs 0.000 description 2
- FSLPMRQHCOLESF-SFMCKYFRSA-N alpha-amyrin Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C FSLPMRQHCOLESF-SFMCKYFRSA-N 0.000 description 2
- SJMCNAVDHDBMLL-UHFFFAOYSA-N alpha-amyrin Natural products CC1CCC2(C)CCC3(C)C(=CCC4C5(C)CCC(O)CC5CCC34C)C2C1C SJMCNAVDHDBMLL-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 2
- 235000006533 astragalus Nutrition 0.000 description 2
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 2
- 235000004883 caffeic acid Nutrition 0.000 description 2
- 229940074360 caffeic acid Drugs 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 2
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- WQLVFSAGQJTQCK-VKROHFNGSA-N diosgenin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)CC4=CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 WQLVFSAGQJTQCK-VKROHFNGSA-N 0.000 description 2
- WQLVFSAGQJTQCK-UHFFFAOYSA-N diosgenin Natural products CC1C(C2(CCC3C4(C)CCC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 WQLVFSAGQJTQCK-UHFFFAOYSA-N 0.000 description 2
- 238000007908 dry granulation Methods 0.000 description 2
- 235000004132 ellagic acid Nutrition 0.000 description 2
- 229960002852 ellagic acid Drugs 0.000 description 2
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 description 2
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 2
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 2
- 229940025878 hesperidin Drugs 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 229940010454 licorice Drugs 0.000 description 2
- 229960004488 linolenic acid Drugs 0.000 description 2
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 2
- 229940116852 myricetin Drugs 0.000 description 2
- PCOBUQBNVYZTBU-UHFFFAOYSA-N myricetin Natural products OC1=C(O)C(O)=CC(C=2OC3=CC(O)=C(O)C(O)=C3C(=O)C=2)=C1 PCOBUQBNVYZTBU-UHFFFAOYSA-N 0.000 description 2
- 235000007743 myricetin Nutrition 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 210000004233 talus Anatomy 0.000 description 2
- 208000016255 tiredness Diseases 0.000 description 2
- 230000003867 tiredness Effects 0.000 description 2
- 229940035893 uracil Drugs 0.000 description 2
- 229940096998 ursolic acid Drugs 0.000 description 2
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 2
- XMOCLSLCDHWDHP-SWLSCSKDSA-N (+)-Epigallocatechin Natural products C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-SWLSCSKDSA-N 0.000 description 1
- WMBWREPUVVBILR-GHTZIAJQSA-N (+)-gallocatechin gallate Chemical compound O([C@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-GHTZIAJQSA-N 0.000 description 1
- CKUVNOCSBYYHIS-UHFFFAOYSA-N (20R)-ginsenoside Rg3 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(CCC3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1O CKUVNOCSBYYHIS-UHFFFAOYSA-N 0.000 description 1
- PYXFVCFISTUSOO-VUFVRDRTSA-N (20R)-protopanaxadiol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@H]([C@](C)(O)CCC=C(C)C)[C@H]4[C@H](O)C[C@@H]3[C@]21C PYXFVCFISTUSOO-VUFVRDRTSA-N 0.000 description 1
- CKUVNOCSBYYHIS-IRFFNABBSA-N (20S)-ginsenoside Rh2 Chemical compound O([C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O CKUVNOCSBYYHIS-IRFFNABBSA-N 0.000 description 1
- PYXFVCFISTUSOO-HKUCOEKDSA-N (20S)-protopanaxadiol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@H]([C@@](C)(O)CCC=C(C)C)[C@H]4[C@H](O)C[C@@H]3[C@]21C PYXFVCFISTUSOO-HKUCOEKDSA-N 0.000 description 1
- FBFMBWCLBGQEBU-RXMALORBSA-N (2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5s,6r)-2-[[(3s,5r,6s,8r,9r,10r,12r,13r,14r,17s)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-17-[(2s)-6-methyl-2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecah Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O FBFMBWCLBGQEBU-RXMALORBSA-N 0.000 description 1
- WHAAPCGHVWVUEX-GGWOSOGESA-N (E,E)-Piperlonguminine Chemical compound CC(C)CNC(=O)\C=C\C=C\C1=CC=C2OCOC2=C1 WHAAPCGHVWVUEX-GGWOSOGESA-N 0.000 description 1
- FTVWIRXFELQLPI-ZDUSSCGKSA-N (S)-naringenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-ZDUSSCGKSA-N 0.000 description 1
- CKUVNOCSBYYHIS-LGYUXIIVSA-N 20(R)-Ginsenoside Rh2 Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1C(C)(C)[C@H]2[C@@](C)([C@H]3[C@](C)([C@@]4(C)[C@H]([C@H](O)C3)[C@@H]([C@](O)(CC/C=C(\C)/C)C)CC4)CC2)CC1 CKUVNOCSBYYHIS-LGYUXIIVSA-N 0.000 description 1
- LNCSXXRCEFAYFK-XNTDXEJSSA-N 4,5-dimethoxy-2-prop-2-enyl-4-[(e)-1-(3,4,5-trimethoxyphenyl)prop-1-en-2-yl]cyclohexa-2,5-dien-1-one Chemical compound COC1=CC(=O)C(CC=C)=CC1(OC)C(\C)=C\C1=CC(OC)=C(OC)C(OC)=C1 LNCSXXRCEFAYFK-XNTDXEJSSA-N 0.000 description 1
- 239000001606 7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one Substances 0.000 description 1
- 101150060184 ACHE gene Proteins 0.000 description 1
- 102100033639 Acetylcholinesterase Human genes 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000124001 Alcyonacea Species 0.000 description 1
- 241001127714 Amomum Species 0.000 description 1
- 241000132012 Atractylodes Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- COZMWVAACFYLBI-UHFFFAOYSA-N Chebulic acid Natural products OC1=C(O)C(O)=C2C(C(CC(=O)O)C(O)=O)C(C(O)=O)OC(=O)C2=C1 COZMWVAACFYLBI-UHFFFAOYSA-N 0.000 description 1
- 229920002361 Chebulic acid Polymers 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 241000007126 Codonopsis pilosula Species 0.000 description 1
- 240000004270 Colocasia esculenta var. antiquorum Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 235000015001 Cucumis melo var inodorus Nutrition 0.000 description 1
- 240000002495 Cucumis melo var. inodorus Species 0.000 description 1
- 102100025191 Cyclin-A2 Human genes 0.000 description 1
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 1
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 description 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 1
- 101100457345 Danio rerio mapk14a gene Proteins 0.000 description 1
- 101100457347 Danio rerio mapk14b gene Proteins 0.000 description 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 1
- 102100038595 Estrogen receptor Human genes 0.000 description 1
- 102100029951 Estrogen receptor beta Human genes 0.000 description 1
- 229930182603 Euscaphic acid Natural products 0.000 description 1
- UFNDONGOJKNAES-UHFFFAOYSA-N Ginsenoside Rb1 Natural products CC(=CCCC(C)(OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CC(O)C45C)C UFNDONGOJKNAES-UHFFFAOYSA-N 0.000 description 1
- HYPFYJBWSTXDAS-UHFFFAOYSA-N Ginsenoside Rd Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C4CCC5C(C)(C)C(CCC5(C)C4CC(O)C23C)OC6OC(CO)C(O)C(O)C6OC7OC(CO)C(O)C(O)C7O)C HYPFYJBWSTXDAS-UHFFFAOYSA-N 0.000 description 1
- UZIOUZHBUYLDHW-MSJHMJQNSA-N Ginsenoside Rf Natural products O([C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@@H]1O[C@@H]1[C@H]2C(C)(C)[C@@H](O)CC[C@]2(C)[C@@H]2[C@](C)([C@@]3(C)[C@H]([C@@H](O)C2)[C@@H]([C@@](O)(CC/C=C(\C)/C)C)CC3)C1)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 UZIOUZHBUYLDHW-MSJHMJQNSA-N 0.000 description 1
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 1
- 102100038104 Glycogen synthase kinase-3 beta Human genes 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- LNCSXXRCEFAYFK-UHFFFAOYSA-N Hancinone C Natural products COC1=CC(=O)C(CC=C)=CC1(OC)C(C)=CC1=CC(OC)=C(OC)C(OC)=C1 LNCSXXRCEFAYFK-UHFFFAOYSA-N 0.000 description 1
- 101000934320 Homo sapiens Cyclin-A2 Proteins 0.000 description 1
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 description 1
- 101000882584 Homo sapiens Estrogen receptor Proteins 0.000 description 1
- 101001010910 Homo sapiens Estrogen receptor beta Proteins 0.000 description 1
- 101001064870 Homo sapiens Lon protease homolog, mitochondrial Proteins 0.000 description 1
- 101001128158 Homo sapiens Nanos homolog 2 Proteins 0.000 description 1
- 101001128156 Homo sapiens Nanos homolog 3 Proteins 0.000 description 1
- 101001124309 Homo sapiens Nitric oxide synthase, endothelial Proteins 0.000 description 1
- 101001124991 Homo sapiens Nitric oxide synthase, inducible Proteins 0.000 description 1
- 101000602930 Homo sapiens Nuclear receptor coactivator 2 Proteins 0.000 description 1
- 101000741790 Homo sapiens Peroxisome proliferator-activated receptor gamma Proteins 0.000 description 1
- 101000605122 Homo sapiens Prostaglandin G/H synthase 1 Proteins 0.000 description 1
- 101000655897 Homo sapiens Serine protease 1 Proteins 0.000 description 1
- 101000595531 Homo sapiens Serine/threonine-protein kinase pim-1 Proteins 0.000 description 1
- 101001087394 Homo sapiens Tyrosine-protein phosphatase non-receptor type 1 Proteins 0.000 description 1
- 208000033830 Hot Flashes Diseases 0.000 description 1
- 206010060800 Hot flush Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108700012928 MAPK14 Proteins 0.000 description 1
- 101150003941 Mapk14 gene Proteins 0.000 description 1
- 102000054819 Mitogen-activated protein kinase 14 Human genes 0.000 description 1
- 102100028452 Nitric oxide synthase, endothelial Human genes 0.000 description 1
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 1
- 102100037226 Nuclear receptor coactivator 2 Human genes 0.000 description 1
- RINSJDWDXSWUOK-UHFFFAOYSA-N OC(=O)C1=CC=C(O)C(O)=C1.OC(=O)C1=CC=C(O)C(O)=C1 Chemical compound OC(=O)C1=CC=C(O)C(O)=C1.OC(=O)C1=CC=C(O)C(O)=C1 RINSJDWDXSWUOK-UHFFFAOYSA-N 0.000 description 1
- 244000248557 Ophiopogon japonicus Species 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 1
- 241001522129 Pinellia Species 0.000 description 1
- WHAAPCGHVWVUEX-UHFFFAOYSA-N Piperlonguminine Natural products CC(C)CNC(=O)C=CC=CC1=CC=C2OCOC2=C1 WHAAPCGHVWVUEX-UHFFFAOYSA-N 0.000 description 1
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 102100032491 Serine protease 1 Human genes 0.000 description 1
- 102100036077 Serine/threonine-protein kinase pim-1 Human genes 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 102100033001 Tyrosine-protein phosphatase non-receptor type 1 Human genes 0.000 description 1
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000003616 anti-epidemic effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- PYXFVCFISTUSOO-UHFFFAOYSA-N betulafolienetriol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC(C(C)(O)CCC=C(C)C)C4C(O)CC3C21C PYXFVCFISTUSOO-UHFFFAOYSA-N 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- OVYQSRKFHNKIBM-UHFFFAOYSA-N butanedioic acid Chemical compound OC(=O)CCC(O)=O.OC(=O)CCC(O)=O OVYQSRKFHNKIBM-UHFFFAOYSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- COZMWVAACFYLBI-XJEVXTIOSA-N chebulic acid Chemical compound OC1=C(O)C(O)=C2[C@H]([C@H](CC(=O)O)C(O)=O)[C@@H](C(O)=O)OC(=O)C2=C1 COZMWVAACFYLBI-XJEVXTIOSA-N 0.000 description 1
- 239000010227 chenpi Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- OXVUXGFZHDKYLS-QUFHAEKXSA-N euscaphic acid Chemical compound C1[C@@H](O)[C@@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@](O)(C)[C@H]5C4=CC[C@@H]3[C@]21C OXVUXGFZHDKYLS-QUFHAEKXSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 description 1
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 description 1
- UZIOUZHBUYLDHW-XUBRWZAZSA-N ginsenoside Rf Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@H]2C(C)(C)[C@@H](O)CC[C@]2(C)[C@H]2C[C@@H](O)[C@H]3[C@@]([C@@]2(C1)C)(C)CC[C@@H]3[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZIOUZHBUYLDHW-XUBRWZAZSA-N 0.000 description 1
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 description 1
- CBEHEBUBNAGGKC-UHFFFAOYSA-N ginsenoside Rg1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CC(OC6OC(CO)C(O)C(O)C6O)C34C)C CBEHEBUBNAGGKC-UHFFFAOYSA-N 0.000 description 1
- PWAOOJDMFUQOKB-UHFFFAOYSA-N ginsenoside b2 Chemical compound OC1C(O)C(O)C(C)OC1OC1C(OC2C3C(C)(C)C(O)CCC3(C)C3C(C4(CCC(C4C(O)C3)C(C)(CCC=C(C)C)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2)OC(CO)C(O)C1O PWAOOJDMFUQOKB-UHFFFAOYSA-N 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- WGEYAGZBLYNDFV-UHFFFAOYSA-N naringenin Natural products C1(=O)C2=C(O)C=C(O)C=C2OC(C1)C1=CC=C(CC1)O WGEYAGZBLYNDFV-UHFFFAOYSA-N 0.000 description 1
- 229940117954 naringenin Drugs 0.000 description 1
- 235000007625 naringenin Nutrition 0.000 description 1
- 229930019673 naringin Natural products 0.000 description 1
- DFPMSGMNTNDNHN-ZPHOTFPESA-N naringin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=CC(O)=CC=2)O[C@H](CO)[C@@H](O)[C@@H]1O DFPMSGMNTNDNHN-ZPHOTFPESA-N 0.000 description 1
- 229940052490 naringin Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- ACXGEQOZKSSXKV-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O.CCCCCCCC(O)=O ACXGEQOZKSSXKV-UHFFFAOYSA-N 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000009702 powder compression Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- ODSVXDFDFCXJDV-UHFFFAOYSA-N tritetracontan-22-one Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)CCCCCCCCCCCCCCCCCCCCC ODSVXDFDFCXJDV-UHFFFAOYSA-N 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- UOJAEODBOCLNBU-UHFFFAOYSA-N vinaginsenoside R4 Natural products C1CC(C2(CC(O)C3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O UOJAEODBOCLNBU-UHFFFAOYSA-N 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/738—Rosa (rose)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提供一种用于新冠肺炎感染恢复期的中药组合物,其由以下重量份的原料制备而成:人参0.5~5份,淮山1~30份,黄精2~15份,芡实1~15份,苡仁2~30份,陈皮3~10份,余甘子1~18份,缫丝花1~15份,红茶1‑10份。以及,提供该用于新冠肺炎感染恢复期的中药组合物的制备方法。所述用于新冠肺炎感染恢复期的中药组合物的配方成分‑靶点‑药理作用机制网络研究结果与主治病症衔接一致,符合现代精准医学原则。同时本品成本低,符合产业化生产需要。
The invention provides a traditional Chinese medicine composition for the recovery period of new coronary pneumonia infection. servings, 2-30 servings of Yiren, 3-10 servings of dried tangerine peel, 1-18 servings of Emblica, 1-15 servings of silk reeling, and 1-10 servings of black tea. And, a preparation method of the traditional Chinese medicine composition for the recovery period of new coronary pneumonia infection is provided. The results of the network research on the formulation components-target-pharmacological action mechanism of the traditional Chinese medicine composition for the recovery period of new coronary pneumonia infection are consistent with the main disease, and are in line with the principles of modern precision medicine. At the same time, the cost of this product is low, which meets the needs of industrialized production.
Description
技术领域technical field
本发明属于保健品技术领域,具体涉及一种用于新冠肺炎感染恢复期的中 药组合物及其制备方法。The invention belongs to the technical field of health care products, and in particular relates to a traditional Chinese medicine composition used for the recovery period of new coronary pneumonia infection and a preparation method thereof.
背景技术Background technique
新型冠状病毒肺炎(COVID-19,新冠肺炎)是由一种新发现的冠状病毒 (SevereAcute Respiratory Syndrome-Coronavirus-2,SARS-CoV-2)感染引起的 急性传染性疾病。该病作为急性呼吸道传染病已纳入《中华人民共和国传染防 治法》规定的乙类传染病,按甲类传染病管理。通过采取一系列预防控制和医 疗救治措施,我国境内疫情上升的势头得到遏制。随着对疾病临床表现、病理 认识的深入和诊疗经验的积累,为进一步加强对该病的早诊早治,提高治愈率, 降低病亡率,相关的预防、检测和治疗的新技术、新方法的亟需被开发应用。Novel coronavirus pneumonia (COVID-19, new coronary pneumonia) is an acute infectious disease caused by a newly discovered coronavirus (SevereAcute Respiratory Syndrome-Coronavirus-2, SARS-CoV-2). As an acute respiratory infectious disease, the disease has been included in the Class B infectious disease stipulated in the Law of the People's Republic of China on the Prevention and Control of Infections, and is managed as a Class A infectious disease. Through the adoption of a series of preventive control and medical treatment measures, the upward trend of the epidemic situation in my country has been contained. With the deepening of the clinical manifestations and pathological understanding of the disease and the accumulation of diagnosis and treatment experience, in order to further strengthen the early diagnosis and early treatment of the disease, improve the cure rate, and reduce the mortality rate, related prevention, detection and treatment of new technologies, new The method urgently needs to be developed and applied.
虽然出院患者均已达到以炎症改善及传染性消失为主要指标的出院标准, 但相当部分患者仍然存在临床不适。北京中医药大学东直门医院的研究团队经 统计后发现,出院患者存在轻度干咳、气短等至少1项呼吸系统不适症状者接 近67%。随着国内采取科学的防控措施以及全体抗疫人员的共同努力下,疫情 得到了有效的控制,大部分病例已治愈出院,预计恢复期患者的康复治疗将逐 步成为新的治疗需求。Although all discharged patients have reached the discharge standard with improvement of inflammation and disappearance of infectivity as the main indicators, a considerable number of patients still have clinical discomfort. After statistics, the research team of Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine found that nearly 67% of discharged patients had at least one symptom of respiratory discomfort such as mild dry cough and shortness of breath. With the adoption of scientific prevention and control measures in China and the joint efforts of all anti-epidemic personnel, the epidemic has been effectively controlled, and most of the cases have been cured and discharged. It is expected that the rehabilitation treatment of patients in the convalescent period will gradually become a new treatment demand.
在最新版的新冠肺炎诊疗方案中,对于恢复期患者的推荐处方为法半夏9 g、陈皮10g、党参15g、炙黄芪30g、炒白术10g、茯苓15g、藿香10g,砂 仁6g(后下)、甘草6g。有学者对2020年3月5日之前卫生主管部门发布的 新冠肺炎防治方案中关于恢复期的中药处方进行统计,药物以补虚药、清热药 及化湿药为主,前5位高频药物分别为甘草、茯苓、陈皮、麦冬和黄芪。然而, 新冠肺炎病程较长,易耗伤正气,恢复期具有正气虚弱而余邪未尽的特点,常 见的临床表现包括气短,倦怠乏力,纳差呕恶,痞满,大便无力,便溏不爽, 舌淡胖,苔白腻等。因此,新冠肺炎恢复期患者的后续治疗改进相当重要。In the latest version of the new coronary pneumonia diagnosis and treatment plan, the recommended prescriptions for convalescent patients are 9 g of Pinellia Fructus, 10 g of dried tangerine peel, 15 g of Codonopsis pilosula, 30 g of Zhi Astragalus, 10 g of Fried Atractylodes, 15 g of Poria, 10 g of Huoxiang, and 6 g of Amomum radix (later). bottom), licorice 6g. Some scholars have counted the Chinese medicine prescriptions for the recovery period in the new coronary pneumonia prevention and treatment plan issued by the health authorities before March 5, 2020. The medicines are mainly tonic, heat-clearing and damp-removing medicines. The top 5 high-frequency medicines They are Licorice, Poria, Chenpi, Ophiopogon japonicus and Astragalus. However, the course of COVID-19 is long, and it is easy to damage the righteousness. During the recovery period, the righteousness is weak and the remaining evils are not exhausted. Common clinical manifestations include shortness of breath, fatigue, anorexia, nausea, fullness, weak stools, and unpleasant stools. , Tongue fat, greasy coating and so on. Therefore, it is very important to improve the follow-up treatment of patients in the convalescent period of new coronary pneumonia.
发明内容SUMMARY OF THE INVENTION
本发明所要解决的技术问题在于克服现有技术之缺陷,提供一种用于新冠 肺炎感染恢复期的中药组合物及其制备方法。The technical problem to be solved by the present invention is to overcome the defects of the prior art, and to provide a traditional Chinese medicine composition for the recovery period of new coronary pneumonia infection and a preparation method thereof.
本发明提供一种用于新冠肺炎感染恢复期的中药组合物,其由以下重量份 的原料制备而成:The present invention provides a kind of traditional Chinese medicine composition for new coronary pneumonia infection recovery period, and it is prepared from the following raw materials by weight:
人参0.5~5份,0.5 to 5 servings of ginseng,
淮山1~30份,1 to 30 portions of Huaishan,
黄精2~15份,2 to 15 servings of Huang Jing,
芡实1~15份,Gorgon 1 to 15 servings,
苡仁2~30份,Yi Ren 2 to 30 servings,
陈皮3~10份,3-10 servings of dried tangerine peel,
余甘子1~18份,1-18 servings of Embergia,
缫丝花1~15份,1-15 servings of silk reeling flowers,
红茶1-10份。1-10 servings of black tea.
以及,一种上述用于新冠肺炎感染恢复期的中药组合物的制备方法,其包 括如下步骤:And, a kind of above-mentioned preparation method of the traditional Chinese medicine composition for new coronary pneumonia infection convalescence, it comprises the steps:
按照上述用于新冠肺炎感染恢复期的中药组合物的重量份称取原料,将淮 山、黄精、芡实、苡仁、陈皮、余甘子、缫丝花和红茶混合,加5~20倍质量份 的水浸泡15~60分钟,加热回流提取0.5~2小时,80~200目过滤,得第一提取 液;The raw materials are weighed according to the weight parts of the above-mentioned traditional Chinese medicine composition for the recovery period of new coronary pneumonia infection, and the Chinese yam, Polygonatum chinensis, Gorgon, yiren, dried tangerine peel, Emblica, silk reeling flower and black tea are mixed, and 5 to 20 times the mass of water is added. Soak for 15-60 minutes, heat and reflux for extraction for 0.5-2 hours, and filter with 80-200 mesh to obtain the first extract;
向药渣中加5~20倍质量份的水回流提取0.5~2小时,80~200目过滤,得 第二提取液;Add 5~20 times mass parts of water to the medicinal residues for reflux extraction for 0.5~2 hours, and filter with 80~200 meshes to obtain the second extract;
将第一提取液和第二提取液混合浓缩,加入人参,获得所述用于新冠肺炎 感染恢复期的中药组合物。The first extraction solution and the second extraction solution are mixed and concentrated, and ginseng is added to obtain the described traditional Chinese medicine composition for the recovery period of new coronary pneumonia infection.
本发明用于新冠肺炎感染恢复期的中药组合物由人参及淮山、黄精、芡实、 苡仁、陈皮、余甘子、缫丝花、红茶提取物组成,共奏补气养阴,健脾益肺之 功,用于肺脾气虚之新冠肺炎患者恢复期的治疗。其具有组方合理、作用显著、 活性成分明确、作用靶点和药理效应清晰、以及原料广、成本低、制备精良、 服用方便等特点,适用于恢复期肺脾气虚的新冠肺炎患者,具有益气养津、补 肺健脾之功效,缓解临床上的不适症状。The traditional Chinese medicine composition used in the recovery period of new coronary pneumonia infection of the present invention is composed of ginseng and yam, rhizoma rhizoma, gorgonian, yiren, tangerine peel, emblica, silk reeling flower, and black tea extracts, which together play the role of invigorating qi and nourishing yin, strengthening the spleen and benefiting the lungs. It is used for the treatment of new coronary pneumonia patients with lung and spleen deficiency during the recovery period. It has the characteristics of reasonable formulation, significant effect, clear active ingredients, clear target and pharmacological effect, wide range of raw materials, low cost, excellent preparation, and convenient administration. Nourishes qi, nourishes the lungs and strengthens the spleen, and relieves clinical symptoms.
附图说明Description of drawings
图1是本发明实施例提供的用于新冠肺炎感染恢复期的中药组合物的中药 原料-活性成分-作用靶点关联网络图。Fig. 1 is the traditional Chinese medicine raw material-active ingredient-action target correlation network diagram of the traditional Chinese medicine composition for new coronary pneumonia infection convalescence provided by the embodiment of the present invention.
具体实施方式Detailed ways
为了使本发明的目的、技术方案及优点更加清楚明白,以下结合附图及实 施例,对本发明进行进一步详细说明。应当理解,此处所描述的具体实施例仅 仅用以解释本发明,并不用于限定本发明。In order to make the objects, technical solutions and advantages of the present invention more clearly understood, the present invention will be further described in detail below with reference to the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention, but not to limit the present invention.
本发明实施例提供一种用于新冠肺炎感染恢复期的中药组合物,其由以下 重量份的原料制备而成:The embodiment of the present invention provides a kind of traditional Chinese medicine composition for new coronary pneumonia infection recovery period, and it is prepared from the following raw materials by weight:
人参0.5~5份,0.5 to 5 servings of ginseng,
淮山1~30份,1 to 30 portions of Huaishan,
黄精2~15份,2 to 15 servings of Huang Jing,
芡实1~15份,Gorgon 1 to 15 servings,
苡仁2~30份,Yi Ren 2 to 30 servings,
陈皮3~10份,3-10 servings of dried tangerine peel,
余甘子1~18份,1-18 servings of Embergia,
缫丝花1~15份,1-15 servings of silk reeling flowers,
红茶1-10份。1-10 servings of black tea.
优选地,所述用于新冠肺炎感染恢复期的中药组合物的制备原料还包括蛋 白核小球藻1~6份,海藻糖1~6份,低聚甘露糖1~3份。低聚甘露糖可直接进 入大肠内为双歧杆菌所利用,促进双歧杆菌增殖同时产生多种有机酸。降低肠 道pH值,抑制有害菌生长,使益生菌在肠道大量增殖,从而调节肠道功能。 更优选地,所述蛋白核小球藻6份,海藻糖6份,低聚甘露糖1.5份。Preferably, the raw materials for the preparation of the traditional Chinese medicine composition for the recovery period of the new coronary pneumonia infection further include 1-6 parts of Chlorella pyrenoidosa, 1-6 parts of trehalose, and 1-3 parts of mannose. Mannose oligosaccharides can directly enter the large intestine and be utilized by bifidobacteria, promoting the proliferation of bifidobacteria and producing a variety of organic acids at the same time. Reduce intestinal pH, inhibit the growth of harmful bacteria, and make probiotics proliferate in the intestinal tract, thereby regulating intestinal function. More preferably, 6 parts of Chlorella pyrenoidosa, 6 parts of trehalose, and 1.5 parts of mannose.
更优选地,所述用于新冠肺炎感染恢复期的中药组合物由以下重量份的原 料制备而成:人参2~4份,淮山8~10份,黄精8~10份,芡实8~10份,苡仁 8~12份,陈皮8~10份,余甘子8~10份,缫丝花8~10份,红茶4-6份。更具 体地,所述用于新冠肺炎感染恢复期的中药组合物由以下重量份的原料制备而 成:人参3份,淮山9份,黄精9份,芡实9份,苡仁10份,陈皮9份,余甘 子9份,缫丝花9份,红茶5份。More preferably, the traditional Chinese medicine composition for the recovery period of new coronary pneumonia infection is prepared from the following raw materials by weight: 2 to 4 parts of ginseng, 8 to 10 parts of yam, 8 to 10 parts of Polygonatum chinensis, and 8 to 10 parts of Gorgon. , 8 to 12 parts of Yi Ren, 8 to 10 parts of dried tangerine peel, 8 to 10 parts of Emblica, 8 to 10 parts of reeling flower, and 4 to 6 parts of black tea. More specifically, the traditional Chinese medicine composition for the recovery period of new coronary pneumonia infection is prepared from the following raw materials by weight: 3 parts of ginseng, 9 parts of yam, 9 parts of Polygonatum chinensis, 9 parts of Gorgon, 10 parts of Yiren, and 9 parts of dried tangerine peel. , 9 parts of Embergia, 9 parts of silk reeling, 5 parts of black tea.
该用于新冠肺炎感染恢复期的中药组合物由人参,淮山,黄精,芡实,苡 仁,陈皮,余甘子,缫丝花,红茶,蛋白核小球藻,海藻糖,低聚甘露糖组成, 临床主要用于新冠肺炎恢复期(肺脾气虚),轻度咳嗽、气短,神疲肢倦,动则 汁出,纳呆食少,舌淡苔白润,脉缓无力者。网络药理学研究共筛选了102个 潜在活性成分,主要包括人参皂苷(3R)-Protopanaxadiol,(20S)-Protopanaxadiol, (20R)-Protopanaxadiol,ginsenoside rh2,ginsenoside rf,Ginsenoside Rg1, Ginsenoside Rb1,Ginsenoside-Rd,GinsenosideRe;Adenosine(腺苷),diosgenin (薯蓣皂苷元),Garcinone B(福素宁醇B),hancinone C(山蒟酮C), piperlonguminine(荜茇宁酰胺),Uracil(尿嘧啶);caprylic acid(辛酸),ergosterol (麦角固醇),linolenic acid(亚麻酸),chebulic acid(柯子酸),ellagicacid(鞣 花酸),Epigallocatechin gallate(表没食子儿茶素没食子酸酯),Gallic acid(没 食子酸),α-amyrin(α-香树脂醇);hesperidin(橙皮苷),naringenin(柚皮苷);Caffeine(咖啡因),Epigallocatechin(没食子儿茶素),catechin gallate(儿茶素 没食子酸酯),Epigallocatechin gallate(没食子儿茶素没食子酸酯);euscaphic acid (刺梨酸),protocatechuic acid(原儿茶酸),Myricetin(杨梅素),Succinic acid (琥珀酸),Citric Acid(柠檬酸),malic acid(苹果酸),gallic acid(五倍子酸), caffeic acid(咖啡酸),ursolic acid(熊果酸)。对活性成分进行靶点预测,共筛 选了264个靶点,主要包括AR,PTGS2,ESR1,DPP4,NOS2,CDK2,CA2, PRSS1,PTPN1,PTGS1,PIM1,F2,PPARG,ESR2,CCNA2,NCOA2,GSK3B, NOS3,ACHE,MAPK14等。大量药理研究结果显示,该用于新冠肺炎感染恢 复期的中药组合物组分具有改善肺功能、抗病毒、增强免疫、促进消化吸收、 改善负氮平衡等药理功能,从而促进新冠肺炎恢复期患者的早期康复。表1系 统揭示了中药组合物促进新冠肺炎恢复期患者康复的的药效活性物质基础及其 作用靶点与分子机理。The traditional Chinese medicine composition used for the recovery period of new coronary pneumonia infection is composed of ginseng, yam, Polygonatum chinensis, Gorgon, Yiren, dried tangerine peel, Emblica, reeling flower, black tea, Chlorella pyrenoidosa, trehalose, oligosaccharide, clinical Mainly used for the recovery period of new coronary pneumonia (lung and spleen deficiency), mild cough, shortness of breath, tiredness and tiredness of limbs, juice out when moving, lack of appetite, pale tongue with white fur, slow and weak pulse. A total of 102 potential active ingredients were screened in the network pharmacology study, mainly including ginsenosides (3R)-Protopanaxadiol, (20S)-Protopanaxadiol, (20R)-Protopanaxadiol, ginsenoside rh2, ginsenoside rf, Ginsenoside Rg1, Ginsenoside Rb1, Ginsenoside-Rd , GinsenosideRe; Adenosine (adenosine), diosgenin (diosgenin), Garcinone B (forsunin alcohol B), hancinone C (behenone C), piperlonguminine (longunning amide), Uracil (uracil); caprylic acid (caprylic acid), ergosterol (ergosterol), linolenic acid (linolenic acid), chebulic acid (keric acid), ellagic acid (ellagic acid), Epigallocatechin gallate (epigallocatechin gallate), Gallic acid ( gallic acid), alpha-amyrin (alpha-amyrin); hesperidin (hesperidin), naringenin (naringin); Caffeine (caffeine), Epigallocatechin (gallocatechin), catechin gallate (catechin gallate) Ester), Epigallocatechin gallate (gallocatechin gallate); euscaphic acid (spicy acid), protocatechuic acid (protocatechuic acid), Myricetin (myricetin), Succinic acid (succinic acid), Citric Acid (lemon acid) acid), malic acid (malic acid), gallic acid (gallic acid), caffeic acid (caffeic acid), ursolic acid (ursolic acid). Target prediction of active ingredients, a total of 264 targets were screened, mainly including AR, PTGS2, ESR1, DPP4, NOS2, CDK2, CA2, PRSS1, PTPN1, PTGS1, PIM1, F2, PPARG, ESR2, CCNA2, NCOA2, GSK3B, NOS3, ACHE, MAPK14, etc. The results of a large number of pharmacological studies have shown that the components of the traditional Chinese medicine composition used in the recovery period of new coronary pneumonia infection have pharmacological functions such as improving lung function, anti-virus, enhancing immunity, promoting digestion and absorption, and improving negative nitrogen balance, thereby promoting the recovery period of patients with new coronary pneumonia. early recovery. Table 1 systematically discloses the pharmacodynamic and active substance basis and its target and molecular mechanism of traditional Chinese medicine composition to promote the recovery of patients with new coronary pneumonia.
各组分具体作用如表1所示:The specific functions of each component are shown in Table 1:
表1Table 1
气虚是新冠肺炎恢复期的核心病机,《新型冠状病毒肺炎诊疗方案(试行 第七版)》和《新型冠状病毒肺炎恢复期中医康复指导建议(试行)》均提出 此观点。大多数新冠肺炎恢复期患者的气虚表现为咳嗽气短、动则乏力、腹胀 纳差等。虚则补之,是恢复期治疗的主要原则。新冠肺炎的病机演化过程如下: 疫气为风寒湿相兼之邪,禀风之气而具快速染易之能,虽为寒湿之性而性质乖 戾,自上焦直入于肺;肺居上焦,如华盖,受心火温煦,纳营卫之气,而有治 节之能,能输布气血。寒湿入肺,直伤肺阳,治节失常而见喘促,气血津液输 布异常,郁积在肺而成痰瘀之邪;阳气旺盛者,或直解肺之寒湿而病愈,邪盛 者正邪交争于肺而高热,阳气亏虚者,不热或但见午后潮热,肺部寒湿久久难 解;阳气抗邪则寒邪渐解,湿邪黏滞,可郁而化热,或沿三焦下行至中焦脾胃, 或直中焦,故见腹胀便溏等不适;土为金母,子脏来邪,其势渐微,脾胃强则 本病多至此可愈;至恢复期,多见肺脾气虚之象,治疗当以补气健脾为要。Qi deficiency is the core pathogenesis of COVID-19 in the recovery period. This point of view is put forward in both the "New Coronary Virus Pneumonia Diagnosis and Treatment Program (Trial Version 7)" and the "New Coronary Virus Pneumonia Recovery Period TCM Rehabilitation Guidance Suggestions (Trial Version)". Most patients with COVID-19 recovering from qi deficiency are characterized by cough, shortness of breath, fatigue when moving, abdominal distension and anorexia. The main principle of convalescent treatment is to make up for the deficiency. The pathogenesis and evolution of new coronary pneumonia is as follows: Epidemic Qi is an evil that combines wind, cold and dampness. It is endowed with wind and has the ability to quickly contaminate and change. Although it is cold and damp, its nature is surly. Jiao, like a canopy, is warmed by the fire of the heart, absorbs the qi of the camp and guards, and has the ability to control the festival, and can transmit the qi and blood. Cold-dampness enters the lung, directly injuring the lung-yang, dyspnea and shortness of breath, abnormal distribution of qi, blood and body fluids, stagnation in the lung, and phlegm and blood stasis. , when the evil is prosperous, the righteous and evil are fighting in the lungs and have high fever, and when the yang qi is deficient, there is no heat or only hot flashes in the afternoon, and the lungs are cold and damp for a long time. It can be stagnant and turn into heat, or it can go down to the spleen and stomach along the three energizers, or go straight to the middle energizer, so it is uncomfortable to see abdominal distension and loose stools. It can be cured; in the recovery period, symptoms of deficiency of the lung and spleen are more common, and the treatment should be based on tonifying qi and strengthening the spleen.
本发明提供的用于新冠肺炎感染恢复期的中药组合物以大补元气的人参为 主,外加健脾化痰、和胃消纳药,通过调整“后天之本”来恢复各脏腑功能, 并补益肺气,有效改善气虚引起的气短,倦怠乏力,纳差呕恶,痞满,大便无 力,便溏不爽,舌淡胖,苔白腻等症状,适用用于恢复期新冠肺炎患者的治疗, 有助于患者的全面康复。用该中药组合物有效成分明确、作用靶点网络清晰、 参与作用的生理/病理过程明确,如图1所示,配方的成分-靶点-药理作用机制 网络研究结果与感染恢复期患者的需求相符。The traditional Chinese medicine composition for the recovery period of the new coronary pneumonia infection provided by the present invention is mainly based on ginseng, which is rich in vitality, plus spleen and phlegm, and stomach digestion drugs, and restores the functions of various zang-fu organs by adjusting the "acquired foundation". Nourishes Lung Qi, effectively improves symptoms of shortness of breath, fatigue, anorexia, nausea, bloating, weak stool, loose stools, pale tongue, greasy coating and other symptoms caused by Qi deficiency. Contribute to the overall recovery of the patient. The effective components of the traditional Chinese medicine composition are clear, the network of action targets is clear, and the physiological/pathological processes involved in the action are clear. As shown in Figure 1, the results of the network research on the composition-target-pharmacological action mechanism of the formula and the needs of patients in the convalescent period of infection match.
本发明实施例还提供上述用于新冠肺炎感染恢复期的中药组合物的制备方 法,其包括如下步骤:The embodiment of the present invention also provides the above-mentioned preparation method of the traditional Chinese medicine composition for new coronary pneumonia infection recovery period, and it comprises the steps:
按照上述用于新冠肺炎感染恢复期的中药组合物的重量份称取原料,将淮 山、黄精、芡实、苡仁、陈皮、余甘子、缫丝花和红茶混合,加5~20倍质量份 的水浸泡15~60分钟,加热回流提取0.5~2小时,100目过滤,得第一提取液;The raw materials are weighed according to the weight parts of the above-mentioned traditional Chinese medicine composition for the recovery period of new coronary pneumonia infection, and the Chinese yam, Polygonatum chinensis, Gorgon, yiren, dried tangerine peel, Emblica, silk reeling flower and black tea are mixed, and 5 to 20 times the mass of water is added. Soak for 15 to 60 minutes, heat and reflux for extraction for 0.5 to 2 hours, and filter with 100 meshes to obtain the first extract;
向药渣中加5~20倍质量份的水回流提取0.5~2小时,100目过滤,得第二 提取液;Add 5~20 times mass parts of water to the medicinal residues for reflux extraction for 0.5~2 hours, filter with 100 meshes to obtain the second extract;
将第一提取液和第二提取液混合浓缩,加入人参,获得所述用于新冠肺炎 感染恢复期的中药组合物。The first extraction solution and the second extraction solution are mixed and concentrated, and ginseng is added to obtain the described traditional Chinese medicine composition for the recovery period of new coronary pneumonia infection.
优选地,淮山、黄精、芡实、苡仁、陈皮、余甘子、缫丝花和红茶混合, 加8~15倍质量份的水浸泡20~40分钟,加热回流提取0.5~2小时,100目过滤, 得第一提取液;Preferably, Chinese yam, Polygonatum chinensis, Gorgon, yiren, dried tangerine peel, emblica, reeling flower and black tea are mixed, and 8 to 15 times by mass of water is added to soak for 20 to 40 minutes, heated and refluxed for extraction for 0.5 to 2 hours, and filtered with 100 meshes. get the first extract;
向药渣中加8~15倍质量份的水,加热回流提取0.5~2小时,100目过滤, 得第二提取液。Add 8 to 15 times by mass of water to the medicinal residue, heat under reflux for extraction for 0.5 to 2 hours, and filter with 100 mesh to obtain a second extract.
优选地,对所述人参进行超微粉碎后再使用。Preferably, the ginseng is used after ultrafine pulverization.
具体地,将第一提取液和第二提取液合并,70℃减压浓缩至相对密度约为 1.08,得浓缩液,向浓缩液中加入麦芽糊精,搅拌均匀,喷雾干燥(喷嘴进风 温度设为150度,出风口温度80度),即得提取物粉末。向提取物粉末中加入 人参超微粉、蛋白核小球藻、海藻糖、低聚甘露糖,混合均匀;分装,10g/袋, 即得固体饮料。Specifically, the first extraction solution and the second extraction solution were combined, concentrated under reduced pressure at 70° C. to a relative density of about 1.08 to obtain a concentrated solution, added maltodextrin to the concentrated solution, stirred evenly, spray-dried (nozzle inlet air temperature Set to 150 degrees, the air outlet temperature is 80 degrees) to obtain the extract powder. Add ginseng ultrafine powder, Chlorella pyrenoidosa, trehalose, and oligomannose to the extract powder, and mix evenly; pack in 10 g/bag to obtain a solid beverage.
此外,取上述提取物粉末,加入人参超微粉、蛋白核小球藻、海藻糖、低 聚甘露糖,混合均匀,加入85%乙醇制粒,70℃干燥,整粒,进行压片;或者 采用适宜的辅料麦芽糊精、玉米淀粉、小麦粉、蛋白粉等,进行干法制粒或者 粉末直接压片,做成适宜的片剂形式也可。In addition, take the above extract powder, add ginseng ultrafine powder, Chlorella pyrenoidosa, trehalose, oligomannose, mix well, add 85% ethanol to granulate, dry at 70°C, granulate, and perform tablet compression; or use Suitable excipients such as maltodextrin, corn starch, wheat flour, protein powder, etc. can also be made into suitable tablet form by dry granulation or direct powder compression.
产品的最终形式可以是多种,包括粉剂、颗粒、片剂、蜜丸、膏滋、口服 液、糖浆剂等。制备工艺中,干燥方式可以是喷雾干燥、真空干燥、冷冻干燥 等;制粒方法可以是干法制粒、湿法制粒、一步制粒等。优选地,所述浓缩液 选用减压干燥,喷雾干燥法,快速干燥粉末,减少对各类成分的破坏,为产品 的有效性提供支持。The final form of the product can be various, including powder, granule, tablet, honeydew, cream, oral liquid, syrup, etc. In the preparation process, the drying method can be spray drying, vacuum drying, freeze drying, etc.; the granulation method can be dry granulation, wet granulation, one-step granulation, etc. Preferably, the concentrated solution is dried under reduced pressure, spray drying, and powder is rapidly dried to reduce damage to various components and provide support for the effectiveness of the product.
采用药学、食品、保健品等相关法规可以接受的方法,均可以对上述用于 新冠肺炎感染恢复期的中药组合物的中药组分进行提取、浓缩、干燥或粉碎, 进一步加工为产品,保留复方的有效成分,制成适宜的给药形式(包括颗粒剂、 粉剂、口服液、片剂等剂型)或者食品形式如压片糖果、餐粉、固体饮料等形 式,满足市场对相关产品的需求,均属于本发明保护的范围。The traditional Chinese medicine components of the above-mentioned traditional Chinese medicine composition for the recovery period of new coronary pneumonia infection can be extracted, concentrated, dried or pulverized by methods acceptable to relevant laws and regulations on pharmacy, food, health products, etc., and further processed into products, retaining the compound formula. The active ingredients are made into suitable administration forms (including dosage forms such as granules, powders, oral liquids, tablets, etc.) or food forms such as tablet candies, meal powders, solid beverages, etc., to meet the market demand for related products, All belong to the protection scope of the present invention.
以下通过具体配方和制备工艺的实施例来说明上述用于新冠肺炎感染恢复 期的中药组合物及其制备方法。The above-mentioned traditional Chinese medicine composition and its preparation method for the recovery period of new coronary pneumonia infection are described below by the embodiment of specific formula and preparation process.
实施例1:Example 1:
按照用于新冠肺炎感染恢复期的中药组合物的重量份称取原料,淮山9kg, 黄精9kg,芡实9kg,苡仁10kg,陈皮9kg,余甘子9kg,缫丝花9kg,红茶 5kg混合,加720L水浸泡30分钟,加热回流提取1小时,100目过滤,得第 一提取液;The raw materials were weighed according to the parts by weight of the traditional Chinese medicine composition used for the recovery period of new coronary pneumonia infection, 9kg of Chinese yam, 9kg of Polygonatum chinensis, 9kg of Gorgon, 10kg of Yiren, 9kg of dried tangerine peel, 9kg of Emblica, 9kg of silk reeling, 5kg of black tea and mixed with 720L of water. Soak for 30 minutes, heat under reflux for 1 hour, and filter with 100 meshes to obtain the first extract;
向药渣中加720L水回流提取1小时,100目过滤,得第二提取液;Add 720L of water to the medicinal residues for reflux extraction for 1 hour, and filter with 100 meshes to obtain the second extract;
将第一提取液和第二提取液混合浓缩,70℃减压浓缩至相对密度约为1.08, 得浓缩液,加入麦芽糊精,搅拌均匀,喷雾干燥(喷嘴进风温度设为150度, 出风口温度80度),即得提取物粉末,向提取物粉末中加入人参3kg、蛋白核 小球藻6kg、海藻糖6kg、低聚甘露糖1.5kg,混合均匀;分装,10g/袋,即 得固体饮料粉剂。The first extraction solution and the second extraction solution were mixed and concentrated, concentrated under reduced pressure at 70°C to a relative density of about 1.08 to obtain a concentrated solution, added maltodextrin, stirred evenly, and spray-dried (the inlet air temperature of the nozzle was set to 150 degrees, and the The tuyere temperature is 80 degrees) to obtain the extract powder, add 3kg of ginseng, 6kg of Chlorella pyrenoidosa, 6kg of trehalose, 1.5kg of mannose oligosaccharide to the extract powder, and mix well; Obtain solid beverage powder.
实施例2:Example 2:
选择10位新冠肺炎感染恢复期的的患者每日服用实施例1中制备的固体 饮料粉剂,连服两周,未有任何不良反应,有7人不适症状显著缓解。10 patients in the recovery period of new coronary pneumonia infection were selected to take the solid beverage powder prepared in Example 1 every day for two weeks without any adverse reaction, and the discomfort symptoms of 7 people were significantly relieved.
以上所述仅为本发明的较佳实施例而已,并不用以限制本发明,凡在本发 明的精神和原则之内所作的任何修改、等同替换和改进等,均应包含在本发明 的保护范围之内。The above descriptions are only preferred embodiments of the present invention and are not intended to limit the present invention. Any modifications, equivalent replacements and improvements made within the spirit and principles of the present invention shall be included in the protection of the present invention. within the range.
Claims (8)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010698799 | 2020-07-17 | ||
CN2020106987991 | 2020-07-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111991524A true CN111991524A (en) | 2020-11-27 |
Family
ID=73466304
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010890639.7A Pending CN111991524A (en) | 2020-07-17 | 2020-08-29 | Traditional Chinese medicine composition for convalescent period of neocoronary pneumonia infection and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111991524A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113616600A (en) * | 2021-08-05 | 2021-11-09 | 广东汇群中药饮片股份有限公司 | Traditional Chinese medicine compound granule for treating spleen-lung qi deficiency and preparation method thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107551230A (en) * | 2016-07-01 | 2018-01-09 | 蔡晓静 | A kind of pharmaceutical composition for treating children Streptococcus convalescence asthenia of pulmonosplenic qi card |
-
2020
- 2020-08-29 CN CN202010890639.7A patent/CN111991524A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107551230A (en) * | 2016-07-01 | 2018-01-09 | 蔡晓静 | A kind of pharmaceutical composition for treating children Streptococcus convalescence asthenia of pulmonosplenic qi card |
Non-Patent Citations (5)
Title |
---|
刘建文等: "《养生保健的全营养素-小球藻》", 31 January 2008, 中国社会出版社 * |
刘景圣等: "《功能性食品》", 28 February 2005, 中国农业出版社 * |
周幸来等: "《常用中药临证禁忌》", 29 February 2016, 金盾出版社 * |
姜锡瑞等: "《生物发酵产业技术》", 30 May 2016, 中国轻工业出版社 * |
李建生等: "河南省新型冠状病毒肺炎中医辨证治疗思路与方法", 《中医学报》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113616600A (en) * | 2021-08-05 | 2021-11-09 | 广东汇群中药饮片股份有限公司 | Traditional Chinese medicine compound granule for treating spleen-lung qi deficiency and preparation method thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105749179A (en) | Traditional Chinese medicine composition for treating metabolic syndrome | |
CN106177183A (en) | A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja, green tea and Folium Mori | |
CN106177053A (en) | A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja and Pericarpium Citri Reticulatae | |
CN106177434A (en) | A kind of Hyperglycemic health care compositions comprising Radix Puerariae and Rhizoma Polygonati Odorati | |
CN106173605A (en) | A kind of Hyperglycemic health care compositions comprising Radix Puerariae and Herba Dendrobii | |
CN111991524A (en) | Traditional Chinese medicine composition for convalescent period of neocoronary pneumonia infection and preparation method thereof | |
CN106177477A (en) | A kind of health composition for blood sugar lowering, blood fat reducing and blood pressure lowering | |
CN106177432A (en) | A kind of health composition comprising leaf of Cyclocarya paliurus Iljinskaja, Folium Mori, green tea and Rhizoma Polygonati Odorati | |
CN106177054A (en) | A kind of Hyperglycemic health care compositions comprising Cortex Mori and Pericarpium Citri Reticulatae | |
CN101954022B (en) | Chinese medicinal composition for treating lung cancer | |
CN106177479A (en) | A kind of Hyperglycemic health care compositions comprising Herba Dendrobii and Rhizoma Polygonati Odorati | |
CN104398912A (en) | Medicine capable of moistening lung, relieving cough and reducing sputum and preparation method of medicine | |
CN105853901A (en) | Preparation for cancer patients to take during radiotherapy and chemotherapy, and method for preparing preparation | |
CN106177476A (en) | A kind of Hyperglycemic health care compositions comprising Herba Dendrobii and Pericarpium Citri Reticulatae | |
CN104510937A (en) | Traditional Chinese medicinal formula for treating infantile asthma and preparation method for paste of traditional Chinese medicinal formula | |
CN105106499A (en) | Traditional Chinese medicinal composition used after surgical shunting of stenosing cholangitis | |
CN100457169C (en) | Medicine for treating chronic colitis and its preparing process | |
CN105617319A (en) | Preparation method of traditional Chinese medicine composition for treating acute cholecystitis | |
CN103735906A (en) | Chinese herb preparation for treating dry bronchiectasis and preparation method thereof | |
CN106173604A (en) | A kind of Hyperglycemic health care compositions comprising Cortex Mori and Rhizoma Polygonati Odorati | |
CN106177480A (en) | A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja and Herba Dendrobii | |
CN106173606A (en) | A kind of Hyperglycemic health care compositions comprising Cortex Mori and Herba Dendrobii | |
CN104398889A (en) | Traditional Chinese medicine composition capable of expelling phlegm and arresting coughing and preparation method of traditional Chinese medicine composition | |
CN1957980B (en) | Composition of medication in use for preserving health and invigorating qi, and preparation method | |
CN105664048A (en) | Pharmaceutical composition inhibiting gastric cancer cell proliferation and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |